Recombinant immunotoxin targeting mesothelin
AssigneeThe United States of America as represented by the Secretary, Department of Health and Human Service
InventorsIra H. Pastan, John Weldon, Richard Beers
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe United States of America as represented by the Secretary, Department of Health and Human Service
InventorsIra H. Pastan, John Weldon, Richard Beers
Estimating the term…
Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to improved recombinant immunotoxins comprising anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and a Pseudomonas Exotoxin moiety which has been modified to reduce its immunogenicity and protease sensitivity and providing a better cytotoxicity for cells which express mesothelin. The RITs are well-suited for the treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
A chimeric molecule comprising a fusion polypeptide having the formula M-L1-FCS-FL-functional PE domain III, wherein
A fusion polypeptide having the formula FCS-FL-PE functional Domain III, wherein:
Dependencies are inferred from the claim text.